BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience..

波士顿——（商业新闻短讯）——阿斯特里亚治疗公司（纳斯达克：ATXS）是一家专注于开发针对过敏性和免疫性疾病的改变生命疗法的生物制药公司，今天宣布任命医学博士苏尼尔·阿加瓦尔为董事会成员。阿加瓦尔博士拥有20多年的生物技术研究、开发和商业化经验。。

“It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “His extensive drug development and clinical expertise strongly complements our Board’s skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage clinical development with the goal of STAR-0215 becoming the market leader in hereditary angioedema.”.

Astria Therapeutics首席执行官JillC.Milne博士表示：“很高兴欢迎Sunil加入我们的董事会。”。“他丰富的药物开发和临床专业知识有力地补充了我们董事会的技能和经验，我们期待着他的贡献，因为我们将继续推进我们的项目进入后期临床开发阶段，目标是STAR-0215成为遗传性血管性水肿的市场领导者。”。

“I am excited to join the Board at Astria at this important stage as the organization prepares for Phase 3 development of STAR-0215,” said Dr. Agarwal. “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”.

阿加瓦尔博士说：“在阿斯特里亚为STAR-0215的第三阶段开发做准备的这一重要阶段，我很高兴加入董事会。”。“STAR-0215有可能显着改善患者的生活，我期待在这个激动人心的时刻为其进步做出贡献。”。

Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics. Throughout his career, Dr. Agarwal has served in leadership and executive roles in the biopharmaceutical industry. He most recently served as Executive Vice President and Chief Development Officer for Sana Biotechnology and, prior to that, as President of Research and Development at Juno Therapeutics until its acquisition by Celgene.

Agarwal博士目前担任Arvinas的董事会成员，之前是Calithera Biosciences，MyoKardia和玻璃治疗公司的董事会成员。在整个职业生涯中，阿加瓦尔博士一直在生物制药行业担任领导和执行职务。他最近曾担任萨那生物技术公司的执行副总裁兼首席开发官，在此之前，他曾担任Juno Therapeutics公司的研发总裁，直到被Celgene收购。

At Ultragenyx he served as Executive Vice President and Chief Medical Officer and at Genentech as Senior Vice President and Global Development Head. He has led global approvals across multiple indications for Rituxan, Actemra, Xolair, Lucentis, Ocrevus, Mepsevii, Breyanzi, and Gliadel. Dr. Agarwal holds a B.S.

在Ultragenyx担任执行副总裁兼首席医疗官，在Genentech担任高级副总裁兼全球发展负责人。他领导了对Rituxan，Actemra，Xolair，Lucentis，Ocrevus，Mepsevii，Breyanzi和Gliadel的多种适应症的全球批准。Agarwal博士拥有学士学位。

in neurobiology from Cornell University and earned his M.D. from Tufts University School of Medicine. He completed his residency at Children’s National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department..

康奈尔大学神经生物学专业，塔夫茨大学医学院医学博士。他在华盛顿特区的儿童国家医学中心（CNMC）完成了住院治疗，并在CNMC儿科急诊科实习。。

About Astria Therapeutics:

关于Astria Therapeutics：

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema.

Astria Therapeutics是一家生物制药公司，我们的使命是为受过敏性和免疫性疾病影响的患者和家庭带来改变生活的疗法。我们的主要项目STAR-0215是临床开发中用于治疗遗传性血管性水肿的血浆激肽释放酶单克隆抗体抑制剂。

Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn..

我们的第二个程序STAR-0310是一种单克隆抗体OX40拮抗剂，用于治疗特应性皮炎的临床前开发。在我们的网站www.astriatx.com上了解更多关于我们公司的信息，或者在X和Instagram@astriatx以及Facebook和LinkedIn上关注我们。。

Forward Looking Statements:

前瞻性声明：

This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: progressing our programs into later stage clinical development; the potential of STAR-0215 becoming a market leader in hereditary angioedema (HAE) and its potential to improve the lives of HAE patients; and our corporate strategy and vision, including our goal to bring life-changing therapies to patients and families affected by allergic and immunological diseases.

本新闻稿包含适用证券法律法规含义内的前瞻性声明，包括但不限于以下声明：将我们的计划推进后期临床开发；STAR-0215成为遗传性血管性水肿（HAE）市场领导者的潜力及其改善HAE患者生活的潜力；以及我们的公司战略和愿景，包括我们为受过敏性和免疫性疾病影响的患者和家庭带来改变生活的疗法的目标。

The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or 'vision,' and similar words expressions are intended to identify forward-looking statements.

使用诸如但不限于“预期”、“相信”、“继续”、“可能”、“估计”、“预期”、“目标”、“打算”、“可能”、“可能”、“计划”、“潜力”、“预测”、“项目”、“应该”、“目标”、“将会”、“将会”或“愿景”等词语，以及类似的词语表达旨在识别前瞻性陈述。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria’s product candidates and other future conditions.

前瞻性陈述既不是历史事实，也不是未来表现的保证。相反，它们是基于Astria目前对其业务未来、未来计划和战略、未来财务表现、Astria候选产品的临床前和临床结果以及其他未来状况的信念、期望和假设。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be repli.

由于各种重要因素，包括与以下相关的风险和不确定性，实际结果可能与此类前瞻性声明所示的结果存在重大差异：适用法律或法规的变化；我们可能受到其他经济、业务和/或竞争因素不利影响的可能性；药物研究和开发固有的风险，例如：我们的药物发现，临床前和临床开发活动的不良结果，临床前研究结果可能无法复制的风险。